“Working with our partners to translate academic research into clinical practice ensures we can provide patients with the latest thinking and the best options available.”
STEVE FULLER, Business Development
WORK WITH US
Optimising the experimental pathway
We believe in making a difference to patients, caregivers and healthcare professionals, by making new pharmaceutical options available to them. Based in Cambridge, UK, we have developed unique partnerships with academic researchers who share these goals, to define a development strategy that ensures regulatory compliance.
Our partnerships help ensure academic research is translated into clinical trials. By introducing an existing molecule to a disease area, we can create innovative products, to give patients greater choice and improved efficacy of their treatments.
Understanding academic needs
Because we’re a university-backed company, we know what the academic sector needs, on both a development and a commercial level. We’ve partnered with universities and spin-outs on many projects, such as IP licenses and research agreements, to deliver results for patients as efficiently as possible.
UCL and Cycle are finding new uses for drugs in liver disease.
Aarhus University are working with Cycle to fight the developing threat of antibiotic resistance with existing drugs.
The University of Cambridge and Cycle are researching new uses in vascular disease.
I have known members of the Cycle team for many years. We are working together on successful research projects which have led to patent applications Cycle help us to decide on which existing drugs to use in our research. I know that as a joint team we have progressed much further than if we had been separate.
Professor Melinda Duer - University of Cambridge
I contacted Cycle as I read an article about them. It quickly became clear that they were the right partner for an Aarhuis IP project. Since the license agreement was signed, Cycle has introduced patient advocacy groups, suppliers and other universities to the project and development work is progressing well. We are excited about the prospect of commercialising the invention made here in Aarhuis.
Eoin Galligan - Technology Transfer Officer, Aarhus University, Denmark